Industrial Synthesis and Procurement of 3-Chloro-5-Cyanophenyl Boronic Acid

• [Reaction Engineering]: Optimized palladium-catalyzed borylation ensures consistent yields above 85% for scale-up.
• [Logistics & Sourcing]: Factory-direct channels reduce bulk price volatility and secure tonnage quantities.
• [Quality Assurance]: Rigorous HPLC validation guarantees industrial purity levels exceeding 99% for API synthesis.

In the landscape of modern pharmaceutical manufacturing, the reliability of key building blocks dictates the success of downstream API production. 3-chloro-5-cyanophenylboronic acid (CAS: 915763-60-9) has emerged as a critical intermediate for Suzuki-Miyaura cross-coupling reactions, enabling the construction of complex biaryl scaffolds found in kinase inhibitors and oncology therapeutics. For process chemists and supply chain directors, securing a stable synthesis route with verified industrial purity is not merely a technical requirement but a commercial imperative.

This technical brief analyzes the manufacturing scalability, impurity profiles, and procurement strategies associated with this specialized boronic acid. By understanding the transition from laboratory synthesis to plant-scale production, stakeholders can mitigate supply risks and ensure batch-to-batch consistency.

Overview Of Patent Protected Synthesis Methods

The production of (3-chloro-5-cyanophenyl)boronic acid typically involves the palladium-catalyzed borylation of the corresponding aryl halide precursor. While laboratory scales often utilize microwave-assisted heating for speed, industrial implementation requires robust thermal management to maintain safety and yield. The preferred manufacturing process employs bis(pinacolato)diboron or pinacolborane under inert atmosphere conditions to minimize protodeboronation, a common side reaction that compromises assay values.

Recent optimizations in ligand selection have significantly improved reaction kinetics. By utilizing bulky phosphine ligands, manufacturers can achieve higher turnover numbers, reducing catalyst loading costs. This is crucial when evaluating the bulk price per kilogram, as catalyst recovery and recycling become economically viable at tonnage scales. Furthermore, controlling the hydrolysis step is essential to prevent the formation of boroxine anhydrides, which can alter stoichiometry in subsequent coupling reactions.

Scaling Reaction Conditions From Lab To Plant

Transitioning from gram-scale synthesis to multi-kilogram batches introduces challenges in heat transfer and mixing efficiency. Exothermic profiles during the borylation step must be carefully managed to prevent thermal runaways. At NINGBO INNO PHARMCHEM CO.,LTD., production protocols are designed to accommodate these exotherms through controlled addition rates and jacketed reactor cooling, ensuring that the synthesis route remains safe and reproducible regardless of batch size.

Supply chain stability is another critical factor for executives managing long-term projects. Market data indicates significant price disparities between research-grade materials (often priced per 100mg) and commercial-grade tonnage supplies. Sourcing directly from a global manufacturer eliminates intermediary markups, providing a competitive edge in cost goods sold (COGS) calculations for final drug products.

Impurity Control In Boronic Acid Production

For quality assurance teams, the impurity profile is the defining metric of vendor suitability. Common impurities in this molecule include residual palladium, unreacted aryl halides, and homocoupling byproducts. Advanced purification techniques, such as recrystallization from mixed solvent systems, are employed to achieve assay levels suitable for GMP environments. When sourcing high-purity (3-Chloro-5-Cyanophenyl)Boronic Acid, buyers should demand comprehensive analytical data that goes beyond simple HPLC area percent.

Storage stability is also a key consideration. While stable under inert atmosphere at room temperature, exposure to moisture can lead to gradual degradation. Proper packaging in moisture-barrier containers ensures the material retains its specifications during transit and storage.

Technical Specifications and Quality Parameters

The following table outlines the critical quality attributes expected for industrial-grade procurement. These parameters serve as a baseline for COA verification during incoming quality control (IQC).

Parameter	Specification	Test Method
CAS Number	915763-60-9	N/A
Molecular Formula	C7H5BClNO2	N/A
Molecular Weight	181.38 g/mol	Calculation
Assay (Purity)	≥ 99.0% (HPLC)	Area Normalization
Appearance	White to Almost White Powder	Visual
Residual Palladium	≤ 10 ppm	ICP-MS
Storage Conditions	Inert Atmosphere, Room Temp	Stability Study

Regulatory Compliance and Supply Security

Executives must ensure that their chemical suppliers adhere to international regulatory standards, including REACH and TSCA compliance where applicable. A reputable partner like NINGBO INNO PHARMCHEM CO.,LTD. maintains rigorous documentation practices, ensuring that every shipment is accompanied by valid safety data sheets and certificates of analysis. This transparency minimizes regulatory friction during audit phases and accelerates the path to clinical trials.

Moreover, supply continuity is paramount. With a monthly supply capability exceeding one ton, industrial partners can support both Phase I clinical material needs and commercial launch volumes without interruption. This scalability distinguishes true manufacturing partners from trading companies that lack direct production control.

To secure a reliable supply chain for your next project, we recommend validating your vendor's production capacity and quality systems early in the development cycle. For detailed technical data, please contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote.